summit clinical trial tirzepatide SUMMIT: Improves Outcomes and Quality of Life For Patients With HFpEF and Obesity Lilly and Company's SUMMIT trial

12 , e2414141 (2025)

Timing your injection on a day when you can rest if needed also helpsmany patients schedule their dose for Friday evening to allow a weekend buffer

If approved, bimagrumab would likely be reserved for people at higher risk of losing too much muscle: Older adults , where muscle loss can lead to frailty, falls, or functional decline People with very low starting muscle mass , where further loss could affect mobility or metabolic health Those on long-term GLP-1 therapy , especially at higher doses or lower food intake That said, bimagrumab could also have a role in post-weight-loss maintenance

Here's what else to expect from the GLP-1 pills, including their efficacy and availability